Launch of Novo Nordisk’s GLP-1 pill revolutionizes obesity treatment

This Monday, January 5, 2026, Novo Nordisk began marketing the first GLP-1 pill approved for the treatment of obesity in Estados Unidos. The medication, known as the Wegovy pill, contains semaglutide as an active ingredient and represents an oral alternative to existing weekly injections.
The initial 1.5-milligram dose is now available in more than 70,000 U.S. pharmacies, including chains like CVS and Costco. Plataformas select telemedicine companies, such as Ro, LifeMD, Weight Watchers, and GoodRx, also offer the product, making access easier for patients.
Cash-payment prices position the drug as one of the most affordable options on the GLP-1 market. Pacientes without insurance coverage can purchase the initial dose for US$149 per month, a price that extends to the 4-milligram dose until April 15th.
Availability and progressive doses
The higher doses, 9 milligrams and 25 milligrams, will hit shelves by the end of this week. Esses dosage levels cost US$299 per month for those who pay directly, without relying on health plans.
Patients with insurance coverage pay from US$25 per month, depending on plan conditions. The company highlighted that production takes place in facilities in the Estados Unidos, ensuring robust supply from the beginning.
- Starting dose (1.5 mg): US$149/month
- 4 mg dose: US$149/month (until April, then US$199)
- High doses (9 mg and 25 mg): US$299/month
Indications and mechanism of action
The Wegovy pill received FDA approval on December 22, 2025 for chronic weight management in adults with obesity or overweight associated with comorbidities. Além Additionally, it reduces the risk of serious cardiovascular events, such as heart attack or stroke, in patients with established cardiovascular disease.
The medication imitates the hormone GLP-1, suppressing appetite and promoting a feeling of satiety. Diferente of the injections, the pill requires daily intake with a 30-minute wait before eating or drinking.
Phase 3 studies demonstrated an average weight loss of up to 16.6% in 64 weeks with the maximum dose, considering treatment adherence. Mesmo analyzing all participants, regardless of continuity, the reduction reached 13.6%.

Prices and accessibility in the market
The pricing strategy aims to overcome cost barriers that limit the use of GLP-1 injections, whose list prices are around US$1,000 per month. Versões for upfront payments for injections range from $299 to $499, depending on the dose.
The oral pill appears as a new field of competition between Novo Nordisk and Eli Lilly, which is developing a similar drug that is still under regulatory analysis. Analistas projects oral formulas to capture significant share of the global weight loss drug market in the coming years.
Novo Nordisk emphasized that the launch opens up possibilities for more than 100 million Americans living with obesity. The convenience of oral administration attracts patients who avoid injections.
Detailed clinical results
In the OASIS 4 trial, with more than 300 obese adults without diabetes, the 25 milligram dose promoted an average loss of 16.6% of body weight when participants maintained treatment. The analysis including dropouts recorded a 13.6% reduction.
Improvements in cardiometabolic factors, such as glycemic control and blood pressure, accompanied weight loss. The safety profile aligned with that of injectable versions of semaglutide.
Patients should combine the medication with a reduced-calorie diet and increased physical activity for optimal results. Administration requires taking on an empty stomach, with temporary restriction on food and drink.
Distribution and acquisition options
More than 70 thousand points of sale in the Estados Unidos receive the initial product. NovoCare Pharmacy, the company’s direct service, offers home delivery with personalized support.
Digital platforms facilitate remote prescriptions and eligibility verification. The wide distribution network aims to meet immediate demand after recent approval.
The company has prepared robust inventories at American factories, avoiding initial shortages common in previous LPG-1 launches.
Competition and future prospects
Eli Lilly advances with its own oral pill, orforglipron, with a regulatory decision expected in 2026. Novo Nordisk gains an initial advantage by offering an approved oral option first.
The LPG-1 market is growing rapidly, with projections of a billion-dollar value in the next decade. Oral Fórmulas expands access by attracting injection-sensitive patients.
The initiative reinforces our commitment to accessibility, combining pharmaceutical innovation with competitive prices for direct payment.






